Trump Tariff Plan Shakes Pharma Markets

President Donald Trump has announced plans to impose major tariffs on imported pharmaceuticals, targeting a sector previously exempt from such measures. This move has led to significant declines in the stock prices of major U.S. and European pharmaceutical companies, including Pfizer, AbbVie, and Merck. The proposed tariffs are part of Trump's broader strategy to encourage domestic drug manufacturing, though industry analysts argue that such shifts are complex and unlikely to happen quickly. European pharmaceutical leaders have expressed concerns over losing substantial investments to the U.S. unless the EU reforms its regulatory and investment climate. The announcement has intensified global trade tensions and added uncertainty to the pharmaceutical sector, which relies heavily on international supply chains. As the U.S. prepares to implement these tariffs, both domestic and global markets are closely monitoring the situation.